Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The FDA approved golimumab for adults with moderate to severe ulcerative colitis in 2013. In October 2025, the FDA extended approval of Golimumab for use in pediatric UC patients (children weighing at least 15 kg) with moderately to severely active UC. Golimumab is the first and only subcutaneous anti-TNF-alpha therapy approved by the FDA to induce and maintain clinical response in UC patients.
Golimumab) is similarly authorized by the EMA for the treatment of moderate to severe UC …